GlassScriptPhysician profile
Anna Figueiredo
NPI 1902435530
$4,039.24
in general payments reported to CMS, 2019-2025
23 companies · $2,369 in 2025
The $2,369 reported for 2025 was more than what 76% of Pediatric Dermatology providers received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $379 · 2024: $1,291 · 2025: $2,369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,940 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,940.24 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $698.84 | 2023-2025 | |
| Genzyme Corporation | $516.77 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $306.75 | 2024-2025 | |
| Leo Pharma INC. | $253.23 | 2024-2025 | Anzupgo, Adbry |
| Janssen Biotech, INC. | $247.93 | 2024-2025 | Tremfya, Simponi Aria, Simponi |
| Organon LLC | $246.65 | 2024-2025 | Vtama, Hadlima |
| Lilly USA, LLC | $238.17 | 2023-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $215.98 | 2024-2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $202.14 | 2023-2025 | Blu-U, Odomzo |
| Ucb, INC. | $196.13 | 2024-2025 | Bimzelx |
| Amgen INC. | $163.01 | 2024-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $147.96 | 2024-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $125.51 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $109.63 | 2025 | Dupixent, Libtayo |
| Pfizer INC. | $80.76 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $58.11 | 2025 | Nemluvio |
| Botanix Sb INC | $52.03 | 2025 | Sofdra |
| Genentech USA, INC. | $50.37 | 2025 | Xolair |
| Lnhc, INC | $38.61 | 2025 | Zelsuvmi |
| Dermavant Sciences, INC. | $37.10 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.21 | 2023 | Spevigo |
| Almirall LLC | $15.51 | 2025 | Klisyri |
| Paratek Pharmaceuticals, INC. | $13.84 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Figueiredo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.